Literature DB >> 28637288

Validation of a risk assessment instrument for pulmonary arterial hypertension.

Jason Weatherald1,2,3,4, Olivier Sitbon2,3,4, Marc Humbert2,3,4.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 28637288     DOI： 10.1093/eurheartj/ehx301

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  8 in total

1.  Assessing risk in pulmonary arterial hypertension: what we know, what we don't.

Authors:  Raymond L Benza; Harrison W Farber; Mona Selej; Mardi Gomberg-Maitland
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

2.  Usefulness of scoring right ventricular function for assessment of prognostic factors in patients with chronic thromboembolic pulmonary hypertension.

Authors:  Yoshihiro Kamimura; Naoki Okumura; Shiro Adachi; Shigetake Shimokata; Fumitaka Tajima; Yoshihisa Nakano; Akihiro Hirashiki; Toyoaki Murohara; Takahisa Kondo
Journal:  Heart Vessels       Date:  2018-04-27       Impact factor: 2.037

3.  Risk stratification and medical therapy of pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Richard N Channick; Robert P Frantz; Ekkehard Grünig; Zhi Cheng Jing; Olga Moiseeva; Ioana R Preston; Tomas Pulido; Zeenat Safdar; Yuichi Tamura; Vallerie V McLaughlin
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

4.  Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension.

Authors:  R James White; Anton Vonk-Noordegraaf; Stephan Rosenkranz; Ronald J Oudiz; Vallerie V McLaughlin; Marius M Hoeper; Ekkehard Grünig; Hossein-Ardeschir Ghofrani; Murali M Chakinala; Joan A Barberà; Christiana Blair; Jonathan Langley; Adaani E Frost
Journal:  Respir Res       Date:  2019-09-12

5.  Risk Stratification in Pulmonary Arterial Hypertension: Do Not Forget the Patient Perspective.

Authors:  Marc Humbert; Edmund M T Lau
Journal:  Am J Respir Crit Care Med       Date:  2021-03-15       Impact factor: 21.405

6.  Dart to the target: an alternative bull's eye parametric display for European Society of Cardiology / European Respiratory Society goal-orientated risk reduction strategy in pulmonary arterial hypertension.

Authors:  Cihangir Kaymaz; Ozgur Yasar Akbal; Aykun Hakgor; Hacer Ceren Tokgoz; Seda Tanyeri
Journal:  Pulm Circ       Date:  2018-05-16       Impact factor: 3.017

7.  Improved low-risk criteria scores for combination therapy of sildenafil and generic bosentan in patients with congenital heart disease with severe pulmonary hypertension: A prospective open label study.

Authors:  Kritvikrom Durongpisitkul; Paweena Chungsomprasong; Chodchanok Vijarnsorn; Prakul Chanthong; Supaluck Kanjanauthai; Jarupim Soongswang
Journal:  JRSM Cardiovasc Dis       Date:  2021-01-21

8.  ＜Editors' Choice＞ Differential effects of combination therapy on the components of the risk stratification table in patients with idiopathic or heritable pulmonary arterial hypertension in a Japanese population.

Authors:  Masahiro Yoshida; Shiro Adachi; Ryo Imai; Shigetake Shimokata; Yoshihisa Nakano; Toyoaki Murohara; Takahisa Kondo
Journal:  Nagoya J Med Sci       Date:  2021-05       Impact factor: 1.131
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.